

## WEST

[Help](#) [Logout](#)[Main Menu](#) [Search Form](#) [Posting Counts](#) [Show S Numbers](#) [Edit S Numbers](#)[Generate Collection](#)

## Search Results - Record(s) 1 through 12 of 12 returned.

1. Document ID: AU 9871999 A, WO 9855036 A1

Entry 1 of 12

File: DWPI

Dec 21, 1998

DERWENT-ACC-NO: 1999-045446

DERWENT-WEEK: 199919

COPYRIGHT 2000 DERWENT INFORMATION LTD

TITLE: Removal of highly vascularised tissue - includes use of wire made as snare to act as 1 electrode and passage of current through snare tightened around tissue to be removed

[Full](#) [Title](#) [Citation](#) [Front](#) [Review](#) [Classification](#) [Date](#) [Reference](#) [Claims](#) [KWMC](#) [Image](#)

2. Document ID: RU 2112134 C1

Entry 2 of 12

File: DWPI

May 27, 1998

DERWENT-ACC-NO: 1998-608254

DERWENT-WEEK: 199851

COPYRIGHT 2000 DERWENT INFORMATION LTD

TITLE: Hydrate and paraffin bottleneck break up device - has working strands of cable connected in pairs to three-phase current source and uses free strand for connection of additional devices in heater

[Full](#) [Title](#) [Citation](#) [Front](#) [Review](#) [Classification](#) [Date](#) [Reference](#) [Claims](#) [KWMC](#) [Image](#)

3. Document ID: CN 1227607 A, WO 9806248 A2, AU 9739728 A, EP 918797 A2

Entry 3 of 12

File: DWPI

Sep 1, 1999

DERWENT-ACC-NO: 1998-159172

DERWENT-WEEK: 199953

COPYRIGHT 2000 DERWENT INFORMATION LTD

TITLE: Humanised immunoglobulin reactive with alpha-4-beta-7 integrin - used for treating inflammatory disease, pancreatitis, diabetes, asthma, graft versus host disease and sarcoidosis

[Full](#) [Title](#) [Citation](#) [Front](#) [Review](#) [Classification](#) [Date](#) [Reference](#) [Claims](#) [KWMC](#) [Image](#)

4. Document ID: RU 2087978 C1

Entry 4 of 12

File: DWPI

Aug 20, 1997



Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KM/C	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

9. Document ID: BE 799854 A, CA 985509 A, FR 2186434 A, GB 1384346 A, JP 49042523 A, JP 79009573 B, US 3887679 A, ZA 7303631 A

File: DWPI

Entry 9 of 12

DERWENT-ACC-NO: 1973-80747U

DERWENT-WEEK: 197352

COPYRIGHT 2000 DERWENT INFORMATION LTD

TITLE: Separating copper and cobalt - by extraction from soln contg hydrochloric acid

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KM/C	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

10. Document ID: BE 791923 A, DE 2359025 B

File: DWPI

Entry 10 of 12

DERWENT-ACC-NO: 1973-39625U

DERWENT-WEEK: 197328

COPYRIGHT 2000 DERWENT INFORMATION LTD

TITLE: Butt welding strip metal - appts provides quick welds for strip in tube making appts

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KM/C	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

11. Document ID: NL 7011542 A, BE 754593 A, DE 2039362 A, FR 2056727 A

File: DWPI

Entry 11 of 12

DERWENT-ACC-NO: 1971-13047S

DERWENT-WEEK: 197107

COPYRIGHT 2000 DERWENT INFORMATION LTD

TITLE: Dehydrated food product from soya-beans

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KM/C	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

12. Document ID: DE 1644456 A

File: DWPI

Apr 8, 1971

Entry 12 of 12

DERWENT-ACC-NO: 1984-295085

DERWENT-WEEK: 198448

COPYRIGHT 2000 DERWENT INFORMATION LTD

TITLE: New anthraquinone dye for synthetic fibres - prep'd. by adding 1-amino-4-pa ra-anisidine- anthraquinone to double bond of gamma-chloropropylene glycol acrylate

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KM/C	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

Generate Collection

Term	Documents
ACT.DWPI.	100592
ACTS.DWPI.	101657
"1".DWPI.	17085972
1S.DWPI.	1129
(ACT ADJ1 "1").DWPI.	12

including document number

Display Format:

begin 652,653,654

```
< 03apr00 12:13:07 User208760 Session D1506.2
  $0.00 0.049 DialUnits File410
$0.00 Estimated cost File410
$0.01 TYMNET
$0.01 Estimated cost this search
$0.42 Estimated total session cost 0.153 DialUnits
```

SYSTEM:OS - DIALOG OneSearch

File 652:US Patents Fulltext 1971-1979

(c) format only 2000 The Dialog Corp.

\*File 652: Reassignment data current through 12/06/1999 recordings.

Due to recent processing problems, the SORT command is not working.

File 653:US Patents Fulltext 1980-1989

(c) format only 2000 The Dialog Corp.

\*File 653: Reassignment data current through 12/06/1999 recordings.

Due to recent processing problems, the SORT command is not working.

File 654:US Pat.Full. 1990-2000/Mar 28

(c) format only 2000 The Dialog Corp.

\*File 654: Reassignment data current through 12/06/1999 recordings.

Due to recent processing problems, the SORT command is not working.

File 654:US Pat.Full. 1990-2000/Mar 28

(c) format only 2000 The Dialog Corp.

\*File 654: Reassignment data current through 12/06/1999 recordings.

Due to recent processing problems, the SORT command is not working.

Set	Items	Description
---	---	-----
? s	(act(w)1) (30n) (antibod? or hybridoma?)	

Processing

Processing

Processing

Processing

Processing

Processing

Processing

333978 ACT

2955794 1

41482 ANTIBOD?

9208 HYBRIDOMA?

S1 9 (ACT(W)1) (30N) (ANTIBOD? OR HYBRIDOMA?)

? t s1/3/all

1/3/1 (Item 1 from file: 654)

DIALOG(R) File 654:US Pat.Full.

(c) format only 2000 The Dialog Corp. All rts. reserv.

03076195

Utility

4-SUBSTITUTED-4-PIPERIDINE CARBOXAMIDE DERIVATIVES

PATENT NO.: 6,020,347

ISSUED: February 01, 2000 (20000201)

INVENTOR(s): DeLaszlo, Stephen E., Rumson, NJ (New Jersey), US (United States of America)

Hagmann, William K., Westfield, NJ (New Jersey), US (United States of America)

ASSIGNEE(s): Merck & Co Inc, (A U.S. Company or Corporation), Rahway, NJ (New Jersey), US (United States of America)

[Assignee Code(s): 54136]

APPL. NO.: 9-191,902

FILED: November 13, 1998 (19981113)

CROSS REFERENCE TO RELATED APPLICATIONS

This application is based on, and claims priority from, U.S. provisional application Ser. No. 60-065,917 filed Nov. 17, 1997, which is hereby incorporated by reference in its entirety.

FULL TEXT: 1975 lines

1/3/2 (Item 2 from file: 654)  
DIALOG(R) File 654:US Pat.Full.  
(c) format only 2000 The Dialog Corp. All rts. reserv.

03055098

Utility

COMPOSITION OF C-KIT LIGAND, GM-CSF, AND TNF-.ALPHA. AND METHOD OF USE

PATENT NO.: 6,001,803  
ISSUED: December 14, 1999 (19991214)  
INVENTOR(s): Besmer, Peter, New York, NY (New York), US (United States of America)  
Buck, Jochen, New York, NY (New York), US (United States of America)  
Moore, Malcolm A. S., New York, NY (New York), US (United States of America)  
Nocka, Karl, Harvard, MA (Massachusetts), US (United States of America)  
ASSIGNEE(s): Sloan-Kettering Institute for Cancer Research, (A U.S. Company or Corporation), New York, NY (New York), US (United States of America)  
[Assignee Code(s): 1305]  
APPL. NO.: 8-325,240  
FILED: October 20, 1994 (19941020)  
PRIORITY: PCT-US93-03640, WO (World Intellectual Property Org), April 16, 1993 (19930416)

This invention is a continuation-in-part application of U.S. Ser. No. 07-873,962, filed Apr. 23, 1992, now abandoned, the contents of which is incorporated by reference into the present application.

The invention described herein was made in the course of work under Grant No. RO1-CA 32926 and ACS KV246D from the National Institute of Health and American Cancer Society, respectively. The United States Government has certain rights in this invention.

FULL TEXT: 3621 lines

1/3/3 (Item 3 from file: 654)  
DIALOG(R) File 654:US Pat.Full.  
(c) format only 2000 The Dialog Corp. All rts. reserv.

02983724

Utility

METHOD FOR INCREASING THE LEVEL OF STEM CELLS IN PERIPHERAL BLOOD

PATENT NO.: 5,935,565  
ISSUED: August 10, 1999 (19990810)  
INVENTOR(s): Besmer, Peter, New York, NY (New York), US (United States of America)  
Buck, Jochen, New York, NY (New York), US (United States of America)  
Moore, Malcolm A. S., New York, NY (New York), US (United

States of America)  
Nocka, Karl [Harvard, MA (Massachusetts), US (United States of America)]  
ASSIGNEE(s): Sloan-Kettering Institute for Cancer Research, (A U.S. Company or Corporation), New York, NY (New York), US (United States of America)  
[Assignee Code(s): 1305]

APPL. NO.: 8-478,414

FILED: June 07, 1995 (19950607)

This application is a continuation application U.S. Ser. No. 08-341,456, filed Nov. 17, 1995, now U.S. Pat. No. 5,767,074, which is a continuation of U.S. Ser. No. 07-873,962, filed Apr. 23, 1992, now abandoned, a continuation-in-part of PCT International Application No. PCT-US91-06130, filed Aug. 27, 1991, a continuation-in-part of U.S. Ser. No. 07-594,306, filed Oct. 5, 1990, and a continuation-in-part of U.S. Ser. No. 07-573,483, filed Aug. 27, 1990, now abandoned, the contents of which are hereby incorporated by reference.

The invention described herein was made in the course of work under Grant No. R01-CA 32926 and ACS MV246D from the National Institute of Health and American Cancer Society, respectively. The United States Government has certain rights in this invention.

FULL TEXT: 3406 lines

1/3/4 (Item 4 from file: 654)  
DIALOG(R)File 654:US Pat.Full.

(c) format only 2000 The Dialog Corp. All rts. reserv.

02970121

Utility  
METHODS OF INHIBITING CANCER BY USING SUPERFIBRONECTIN

PATENT NO.: 5,922,676

ISSUED: July 13, 1999 (19990713)

INVENTOR(s): Pasqualini, Renata, Solana Beach, CA (California), US (United States of America)  
Ruoslahti, Erkki, Rancho Santa Fe, CA (California), US (United States of America)

ASSIGNEE(s): The Burnham Institute, (A U.S. Company or Corporation), La Jolla, CA (California), US (United States of America)  
[Assignee Code(s): 41683]

APPL. NO.: 8-717,169

FILED: September 20, 1996 (19960920)

This invention was funded in part by NIH Grant Nos. CA62042 and CA30199. Accordingly, the United States government has certain rights in the invention.

FULL TEXT: 1855 lines

1/3/5 (Item 5 from file: 654)

DIALOG(R)File 654:US Pat.Full.

(c) format only 2000 The Dialog Corp. All rts. reserv.

02966962

Utility  
VACCINE FOR CLOSTRIDIUM BOTULINUM NEUROTOXIN

PATENT NO.: 5,919,665

ISSUED: July 06, 1999 (19990706)

INVENTOR(s): Williams, James A., Madison, WI (Wisconsin), US (United States of America)

ASSIGNEE(s): Ophidian Pharmaceuticals, Inc, (A U.S. Company or Corporation), Madison, WI (Wisconsin), US (United States of America)  
[Assignee Code(s): 30373]  
APPL. NO.: 8-405,496  
FILED: March 16, 1995 (19950316)

This application is a Continuation-in-Part of application Ser. No. 08-329,154 filed, Oct. 24, 1994, now abandoned, which is a Continuation-in-Part of application Ser. No. 08-161,907, filed on Dec. 2, 1993, now U.S. Pat. No. 5,601,823; which is a Continuation-in-Part of application Ser. No. 07-985,321, filed Dec. 4, 1992, which is a Continuation-in-Part of application Ser. No. 429,791, filed Oct. 31, 1989 now issued as U.S. Pat. No. 5,196,193 on Mar. 23, 1993.

FULL TEXT: 10143 lines

1/3/6 (Item 6 from file: 654)  
DIALOG(R) File 654:US Pat.Full.  
(c) format only 2000 The Dialog Corp. All rts. reserv.

02952447

Utility  
EPIDERMAL GROWTH FACTOR RECEPTOR TARGETED MOLECULES FOR TREATMENT OF  
INFLAMMATORY ARTHRITIS

PATENT NO.: 5,906,820  
ISSUED: May 25, 1999 (19990525)  
INVENTOR(s): Bacha, Patricia A., Hollis, NH (New Hampshire), US (United States of America)  
ASSIGNEE(s): Seragen, Inc, (A U.S. Company or Corporation), Hopkinton, MA (Massachusetts), US (United States of America)  
[Assignee Code(s): 28198]  
APPL. NO.: 8-851,408  
FILED: May 05, 1997 (19970505)

This is a continuation of application Ser. No. 08-458,719 filed on Jun. 3, 1995 (now abandoned), which is a continuation of Ser. No. 08-116,806 filed on Sep. 3, 1993 (U.S. Pat. No. 5,614,488), which is a continuation of Ser. No. 08-005,871 filed on Jan. 15, 1993 (now abandoned), which is a continuation of Ser. No. 07-726,316 filed on Jul. 5, 1991, now abandoned.  
FULL TEXT: 773 lines

1/3/7 (Item 7 from file: 654)  
DIALOG(R) File 654:US Pat.Full.  
(c) format only 2000 The Dialog Corp. All rts. reserv.

02799866

Utility  
COMPOSITIONS OF SOLUBLE C-KIT LIGAND AND HEMATOPOIETIC FACTORS  
[Comprises a soluble c-kit ligand protein and one or more hematopoietic factors selected from interleukins, granulocyte-macrophage-colony stimulating factor, granulocyte-colony stimulating factor or erythropoietin]

PATENT NO.: 5,767,074  
ISSUED: June 16, 1998 (19980616)  
INVENTOR(s): Besmer, Peter, New York, NY (New York), US (United States of America)  
Buck, Jochen, New York, NY (New York), US (United States of America)  
Moore, Malcolm A.S., New York, NY (New York), US (United States of America)  
Nocka, Karl, Harvard, MA (Massachusetts), US (United States

of America)  
ASSIGNEE(s): Sloan-Kettering Institute for Cancer Research, (A U.S. Company or Corporation), New York, NY (New York), US (United States of America)  
[Assignee Code(s): 1305]  
APPL. NO.: 8-341,456  
FILED: November 17, 1994 (19941117)

This invention is a continuation of U.S. Ser. No. 07-873,962, filed Apr. 23, 1992, now abandoned, which is a continuation-in-part application of PCT-US91-06130, filed Aug. 27, 1991, which is a continuation-in-part of U.S. Ser. No. 594,306, filed Oct. 5, 1990, which in turn is a continuation-in-part of U.S. Ser. No. 573,483, filed Aug. 27, 1990, now abandoned, the contents of all three are hereby incorporated by reference into the present application.

The invention described herein was made in the course of work under Grant No. R01-CA 32926 and ACS MV246D from the National Institute of Health and American Cancer Society, respectively. The United States Government has certain rights in this invention.

FULL TEXT: 3356 lines

1/3/8 (Item 8 from file: 654)  
DIALOG(R)File 654:US Pat.Full.  
(c) format only 2000 The Dialog Corp. All rts. reserv.

02632081

Utility  
EPIDERMAL GROWTH FACTOR RECEPTOR TARGETED MOLECULES FOR TREATMENT OF  
INFLAMMATORY ARTHRITIS  
[Cytotoxic fragment of a peptide toxin]

PATENT NO.: 5,614,488  
ISSUED: March 25, 1997 (19970325)  
INVENTOR(s): Bacha, Patricia A., Hollis, NH (New Hampshire), US (United States of America)  
ASSIGNEE(s): Seragen, Inc, (A U.S. Company or Corporation), Hopkinton, MA (Massachusetts), US (United States of America)  
[Assignee Code(s): 28198]  
APPL. NO.: 8-116,806  
FILED: September 03, 1993 (19930903)

This is a continuation of application Ser. No. 08-005,871, filed Jan. 15, 1993, now abandoned; which is a continuation of 07-726,316, filed Jul. 5, 1991, now abandoned.

FULL TEXT: 759 lines

1/3/9 (Item 9 from file: 654)  
DIALOG(R)File 654:US Pat.Full.  
(c) format only 2000 The Dialog Corp. All rts. reserv.

02314811

Utility  
TREATMENT OF ACCELERATED ATHEOSCLEROSIS WITH INTERLEUKIN-2 RECEPTOR  
TARGETED MOLECULES  
[Cytotoxins]

PATENT NO.: 5,326,559  
ISSUED: July 05, 1994 (19940705)  
INVENTOR(s): Miller, D. Douglas, 7295 Greenway Ave., University City, MO (Missouri), US (United States of America), 63130

[Assignee C (s): 68000]  
APPL. NO.: 7-701,219  
FILED: May 16, 1991 (19910516)  
FULL TEXT: 693 lines  
? t sl/k/all

1/K/1 (Item 1 from file: 654)  
DIALOG(R) File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.  
...stimulated with proinflammatory cytokines." Immunol. 89, 375 (1996)).

At present, there is a humanized monoclonal antibody (Antegren(r) Athena Neurosciences/Elan) against VLA-4 in clinical development for the treatment of "flares" associated with multiple sclerosis and a humanized monoclonal antibody (ACT-1 (r) LeukoSite) against alpha sub 4 beta sub 7 in clinical development for the treatment...

1/K/2 (Item 2 from file: 654)  
DIALOG(R) File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.  
... ZBI (coulter Electronics, Hialeah, Fla.). All plasticware used was of tissue culture grade.

Cytokines and Antibodies. Purified rhIL-1 beta, sp act= 1 .32X10 sub 7 U/mg, (Syntex Laboratories, Inc.,: Palo Alto, Calif.) was used at 100...

1/K/3 (Item 3 from file: 654)  
DIALOG(R) File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.  
... ZBI (coulter Electronics, Hialeah, Fla.). All plasticware used was of tissue culture grade.

#### Cytokines and Antibodies

Purified rhIL-1 beta, sp act=1 .32X10 sub 7 U/mg, (Syntex Laboratories, Inc.,: Palo Alto, Calif.) was used at 100...

1/K/4 (Item 4 from file: 654)  
DIALOG(R) File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.  
... Sheppard (University of California, San Francisco), and the anti- alpha sub 4 beta sub 7 (Act-1) antibody was from Dr. Andrew Lazarovits (University of Western Ontario, Canada).

The migration assays of FIG...

1/K/5 (Item 5 from file: 654)  
DIALOG(R) File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.

1/K/6 (Item 6 from file: 654)  
DIALOG(R) File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.  
... are three ways in which the EGF receptor targeted molecules useful in the invention can act: (1) the ...molecule can kill a cell by virtue of a cytotoxic domain; (2) the molecule (an antibody) can cause cell lysis by inducing complement fixation; or (3) the molecule can block binding...

1/K/7 (Item 7 from file: 654)  
DIALOG(R)File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.  
... ZBI (coulter Electronics, Hialeah, Fla.). All plasticware used was of  
tissue culture grade.

Cytokines and Antibodies. Purified rhIL-1 beta, sp act  
1.32X10 sup 7 mu /mg, (Syntex Laboratories, Inc.,: Palo Alto, Calif.)  
was used at 100...

1/K/8 (Item 8 from file: 654)  
DIALOG(R)File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.  
... are three ways in which the EGF receptor targeted molecules useful in  
the invention can act: (1) the molecule can kill a cell by  
virtue of a cytotoxic domain; (2) the molecule (an antibody) can  
cause cell lysis by inducing complement fixation; or (3) the molecule can  
block binding...

1/K/9 (Item 9 from file: 654)  
DIALOG(R)File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.  
... In general, there are three ways in which the molecules useful in the  
invention can act: (1) the molecule can kill a cell because the  
molecule has a cytotoxic domain; (2) the molecule (an antibody) can  
cause cell lysis by inducing complement fixation; and (3) the molecule can  
block binding...

begin 5,73,155,399

03apr00 12:19:03 User208760 Session D1506.3  
\$3.56 0.604 DialUnits File652  
\$3.56 Estimated cost File652  
\$5.88 0.996 DialUnits File653  
\$5.88 Estimated cost File653  
\$15.53 2.633 DialUnits File654  
\$5.85 9 Type(s) in Format 3  
\$0.00 9 Type(s) in Format 95 (KWIC)  
\$5.85 18 Types  
\$21.38 Estimated cost File654  
OneSearch, 3 files, 4.233 DialUnits FileOS  
\$0.30 TYMNET  
\$31.12 Estimated cost this search  
\$31.54 Estimated total session cost 4.386 DialUnits

SYSTEM:OS - DIALOG OneSearch  
File 5:Biosis Previews(R) 1969-2000/Apr W1  
(c) 2000 BIOSIS  
\*File 5: Updates renamed. See Help News5.  
File 73:EMBASE 1974-2000/Mar W3  
(c) 2000 Elsevier Science B.V.  
\*File 73: New drug links added. See Help News73.  
File 155:MEDLINE(R) 1966-2000/May W4  
(c) format only 2000 Dialog Corporation  
\*File 155: MEDLINE will be reloaded. Accession numbers will change.  
File 399:CA SEARCH(R) 1967-2000/UD=13214  
(c) 2000 American Chemical Society  
\*File 399: Use is subject to the terms of your user/customer agreement.  
RANK charge added; see HELP RATES 399.

Set Items Description  
--- --- ---  
? s (act(w)1) (30n) (antibod? or hybridoma?)

Processing  
182298 ACT  
7136809 1  
1522603 ANTIBOD?  
42436 HYBRIDOMA?  
S1 18 (ACT(W)1) (30N) (ANTIBOD? OR HYBRIDOMA?)  
? rd s1  
...completed examining records  
S2 11 RD S1 (unique items)  
? t s2/3/all

2/3/1 (Item 1 from file: 5)  
DIALOG(R) File 5:Biosis Previews(R)  
(c) 2000 BIOSIS. All rts. reserv.  
10579258 BIOSIS NO.: 199699200403  
Integrin alpha-4-beta-7 mediates human eosinophil interaction with  
MadCAM-1, VCAM-1 and fibronectin.  
AUTHOR: Walsh G M(a); Symon F A; Lazarovits A I; Wardlaw A J  
AUTHOR ADDRESS: (a)Dep. Respiratory Med., Univ. Leicester Med. Sch.,  
Glenfield Hospital, Leicester LE3 9QP\*\*UK  
JOURNAL: Immunology 89 (1):p112-119 1996

ISSN: 0019-2805  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

2/3/2 (Item 2 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2000 BIOSIS. All rts. reserv.

10579256 BIOSIS NO.: 199699200401  
Expression and function of alpha-4/beta-7 integrin on human natural killer  
cells.  
AUTHOR: Perez-Villar J J(a); Zapata J M; Melero I; Postigo A;  
Sanchez-Madrid F; Lopez-Botet M  
AUTHOR ADDRESS: (a)Serv. Immunologia, Hospital de la Princesa, Diego de  
Leon 62, 28006 Madrid\*\*Spain  
JOURNAL: Immunology 89 (1):p96-104 1996  
ISSN: 0019-2805  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

2/3/3 (Item 3 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2000 BIOSIS. All rts. reserv.

08920904 BIOSIS NO.: 199396072405  
CD53, a protein with four membrane-spanning domains, mediates signal  
transduction in human monocytes and B cells.  
AUTHOR: Olweus Johanna(a); Lund-Johansen Fridtjof; Horejsi Vaclav  
AUTHOR ADDRESS: (a)Res. Dep., Becton Dickinson Immunocytometry Systems,  
2350 Qume Drive, San Jose, CA 95131-1807\*\*USA  
JOURNAL: Journal of Immunology 151 (2):p707-716 1993  
ISSN: 0022-1767  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

2/3/4 (Item 4 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2000 BIOSIS. All rts. reserv.

06170627 BIOSIS NO.: 000086004809  
HUMAN CYTOTROPHOBlastic ANTIGENS DEFINED BY MONOCLONAL ANTIBODIES  
AUTHOR: ABE Y; OKAMURA K; HAMAZAKI Y; WADA Y; YAJIMA A  
AUTHOR ADDRESS: DEP. OBSTET. GYNECOL., TOHOKU UNIV. SCH. MED., SENDAI 980.  
JOURNAL: TOHOKU J EXP MED 154 (3). 1988. 245-252.  
FULL JOURNAL NAME: Tohoku Journal of Experimental Medicine  
CODEN: TJEMA  
RECORD TYPE: Abstract  
LANGUAGE: ENGLISH

2/3/5 (Item 5 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2000 BIOSIS. All rts. reserv.

06085943 BIOSIS NO.: 000085049092  
IMMUNOPRECIPITATION OF THE INTERLEUKIN 2 RECEPTOR FROM HODGKIN'S DISEASE  
DERIVED CELL LINES BY MONOCLONAL ANTIBODIES  
AUTHOR: SCHWARTING R; GERDES J; ZIEGLER A; STEIN H  
AUTHOR ADDRESS: FREE UNIV. BERLIN, KLINIKUM STEGLITZ, DEP. PATHOL.,  
HINDENBERGDAMM 30, 100 BERLIN 45, WEST GERMANY.

JOURNAL: HEMATOL ONCOL 5 (1). 1987. 57-64.  
FULL JOURNAL NAME: Hematological Oncology  
CODEN: HAOND  
RECORD TYPE: Abstract  
LANGUAGE: ENGLISH

2/3/6 (Item 6 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2000 BIOSIS. All rts. reserv.

04753088 BIOSIS NO.: 000080056215  
ISOLATION AND CHARACTERIZATION OF RAT PLASMA GLANDULAR KALLIKREIN  
AUTHOR: MASFERRER J; ALBERTINI R; CROXATTO H R; GARCIA P; PINTO I  
AUTHOR ADDRESS: LAB. PHYSIOL., FAC. BIOL. SCI., CATHOLIC UNIV. CHILE,  
CASILLA 114-D, SANTIAGO, CHILE.

JOURNAL: BIOCHEM PHARMACOL 34 (1). 1985. 51-56.  
FULL JOURNAL NAME: Biochemical Pharmacology  
CODEN: BCPCA  
RECORD TYPE: Abstract  
LANGUAGE: ENGLISH

2/3/7 (Item 7 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2000 BIOSIS. All rts. reserv.

04552257 BIOSIS NO.: 000029075294  
A MONOCLONAL ANTIBODY ANTI-ACT-1 DEFINES A NEW LATE  
LYMPHOCYTE ACTIVATION ANTIGEN  
AUTHOR: LAZAROVITIS A I; MOSCICKI R A; CAMERINI D; KURNICK J T; BHAN A K;  
BAIRD L G; ERIKSON M; COSIMI A B; COLVIN R B  
AUTHOR ADDRESS: DEP. PATHOL, MASS. GENERAL HOSP., BOSTON, MASS.  
JOURNAL: MEETING OF THE CANADIAN SOCIETY OF NEPHROLOGY, MONTREAL, QUE.,  
CANADA, SEPT. 10-13, 1984. KIDNEY INT 27 (3). 1985. 594.  
CODEN: KDYIA  
DOCUMENT TYPE: Meeting  
RECORD TYPE: Citation  
LANGUAGE: ENGLISH

2/3/8 (Item 1 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2000 Elsevier Science B.V. All rts. reserv.

07235479 EMBASE No: 1998127277  
Detection of interleukin-2 receptors on tumor cells in formalin-fixed,  
paraffin-embedded tissues  
Levi E.; Butmarc J.; Kourea H.P.; Kadin M.E.  
Dr. M.E. Kadin, Director of Hematopathology, Beth Israel-Deaconess  
Medical Center, Department of Pathology, 330 Brookline Avenue, Boston, MA  
02215 United States  
Applied Immunohistochemistry ( APPL. IMMUNOHISTOCHEM. ) (United States)  
1997, 5/4 (234-238)  
CODEN: APIME ISSN: 1062-3345  
DOCUMENT TYPE: Journal; Article  
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH  
NUMBER OF REFERENCES: 18

2/3/9 (Item 2 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2000 Elsevier Science B.V. All rts. reserv.

06796130 EMBASE No: 1997077633  
Antigenic determinants of prostate-specific antigen (PSA) and development

of assays specific for different forms of PSA  
Nilsson O.; Peter A.; Persson I.; Nilsson K.; Grundström B.; Karlsson  
B.  
O. Nilsson, CanAg Diagnostics AB, Majnabbe Terminal Building, SE-414 55  
Gothenburg Sweden  
British Journal of Cancer ( BR. J. CANCER ) (United Kingdom) 1997, 75/6  
(789-797)  
CODEN: BJCAA ISSN: 0007-0920  
DOCUMENT TYPE: Journal; Article  
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH  
NUMBER OF REFERENCES: 41

2/3/10 (Item 3 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2000 Elsevier Science B.V. All rts. reserv.

06597695 EMBASE No: 1996262400  
Integrin alphainf 4betainf 7 mediates human eosinophil interaction with  
MAdCAM-1, VCAM-1 and fibronectin  
Walsh G.M.; Symon F.A.; Lazarovits A.I.; Wardlaw A.J.  
Department of Respiratory Medicine, University Leicester Medical School,  
Glenfield Hospital, Leicester LE3 9QP United Kingdom  
Immunology ( IMMUNOLOGY ) (United Kingdom) 1996, 89/1 (112-119)  
CODEN: IMMUA ISSN: 0019-2805  
DOCUMENT TYPE: Journal; Article  
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

2/3/11 (Item 4 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2000 Elsevier Science B.V. All rts. reserv.

06597693 EMBASE No: 1996262398  
Expression and function of alphainf 4/betainf 7 integrin on human natural  
killer cells  
Perez-Villar J.J.; Zapata J.M.; Melero I.; Postigo A.; Sanchez-Madrid F.;  
Lopez-Botet M.  
Servicio de Inmunología, Hospital de la Princesa, Diego de Leon 62, 28006  
Madrid Spain  
Immunology ( IMMUNOLOGY ) (United Kingdom) 1996, 89/1 (96-104)  
CODEN: IMMUA ISSN: 0019-2805  
DOCUMENT TYPE: Journal; Article  
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

? t s2/k/all

>>>KWIC option is not available in file(s): 399

2/K/1 (Item 1 from file: 5)  
DIALOG(R)File 5:(c) 2000 BIOSIS. All rts. reserv.

...ABSTRACT: transfectants. Binding of unstimulated eosinophils to VCAM-1  
transflectants was inhibited by HP1/2 (an **antibody** that blocks both  
alpha-4-beta-1 and alpha-4-beta-7 functions), but not **Act-1**,  
an alpha-4-beta-7 monoclonal **antibody** (mAb). PAF stimulation  
resulted in increased binding of eosinophils to MAdCAM-1 transflectants,  
which was inhibited by both HP1/2 and **Act-1**. In contrast, PAF  
did not enhance binding to VCAM-1 transflectants, although binding of PAF  
...

2/K/2 (Item 2 from file: 5)  
DIALOG(R)File 5:(c) 2000 BIOSIS. All rts. reserv.

...ABSTRACT: 7 is induced in NK cells upon activation, as the  
anti-alpha-4-beta-7 **ACT-1** monoclonal **antibody** (mAb)  
faintly stained a minority of peripheral blood NK cells, whereas it  
strongly reacted with in vitro long-term interleukin-2 (IL-2)-activated  
NK cells. Incubation with **ACT-1** or its F(ab')-2 fragments  
induced a strong homotypic adhesion of NK cells, comparable...

2/K/3 (Item 3 from file: 5)  
DIALOG(R)File 5:(c) 2000 BIOSIS. All rts. reserv.

MISCELLANEOUS TERMS: ...MONOCLONAL **ANTIBODY ACT-1**;

2/K/4 (Item 4 from file: 5)  
DIALOG(R)File 5:(c) 2000 BIOSIS. All rts. reserv.

ABSTRACT: Monoclonal **antibodies** have been raised against  
cytotrophoblast. Two different antigens, defined on cytotrophoblast but  
not on syncytiotrophoblast were designated **ACT-1** and **ACT-2**,  
respectively. Chorionic villi were taken from normal early pregnancy and  
processed for...

2/K/5 (Item 5 from file: 5)  
DIALOG(R)File 5:(c) 2000 BIOSIS. All rts. reserv.

...ABSTRACT: the interleukin-2 receptor (IL2-R) was detectable on  
H-RS-cells by three monoclonal **antibodies** (anti-Tac, Tu69 and  
**ACT-1**) with the sensitive alkaline phosphatase anti-alkaline  
phosphatase (APAAP) tissue staining procedure. In extension of...

2/K/6 (Item 6 from file: 5)  
DIALOG(R)File 5:(c) 2000 BIOSIS. All rts. reserv.

...ABSTRACT: ng kinins/min .times. mg) and p-nitroaniline (pNA) from the  
substrate S-2266 (sp. act. 1.23 nmol pNA/min .times. mg); it  
was inhibited by aprotinin, benzamidine and rat urinary antikallikrein  
**antibody** but not by ovomucoid. In polyacrylamide gel

electrophoresis, the enzymatic activities of the preparation were...

2/K/7 (Item 7 from file: 5)  
DIALOG(R)File 5:(c) 2000 BIOSIS. All rts. reserv.

A MONOCLONAL ANTIBODY ANTI-ACT-1 DEFINES A NEW LATE LYMPHOCYTE ACTIVATION ANTIGEN

2/K/8 (Item 1 from file: 73)  
DIALOG(R)File 73:(c) 2000 Elsevier Science B.V. All rts. reserv.

DRUG TERMS (UNCONTROLLED): monoclonal antibody act 1

2/K/9 (Item 2 from file: 73)  
DIALOG(R)File 73:(c) 2000 Elsevier Science B.V. All rts. reserv.

...and PSA-ACT. Assays specific for F-PSA (cross-reactivity between F-PSA and PSA-ACT < 1%) were developed by the combination of **antibodies** recognizing epitopes exposed only in F-PSA and **antibodies** recognizing epitopes exposed both in F-PSA and PSA-ACT.

2/K/10 (Item 3 from file: 73)  
DIALOG(R)File 73:(c) 2000 Elsevier Science B.V. All rts. reserv.

...transfектants. Binding of unstimulated eosinophils to VCAM-1 transfектants was inhibited by HP1/2 (an **antibody** that blocks both alphainf 4betainf 1 and alphainf 4betainf 7 functions), but not **Act-1**, an alphainf 4betainf 7 monoclonal **antibody** (mAb). PAF stimulation resulted in increased binding of eosinophils to MAdCAM-1 transfектants, which was inhibited by both HP1/2 and **Act-1**. In contrast, PAF did not enhance binding to VCAM-1 transfектants, although binding of PAF...

2/K/11 (Item 4 from file: 73)  
DIALOG(R)File 73:(c) 2000 Elsevier Science B.V. All rts. reserv.

...4betainf 7 is induced in NK cells upon activation, as the anti-alphainf 4betainf 7 **ACT-1** monoclonal **antibody** (mAb) faintly stained a minority of peripheral blood NK cells, whereas it strongly reacted with in vitro long-term interleukin-2 (IL-2)-activated NK cells. Incubation with **ACT-1** or its F(ab')inf 2 fragments induced a strong homotypic adhesion of NK cells...